The Board approves the Quality Assurance Policy for Pharmaceutical Products ("QA Policy") as set out in Annex 1 to the Report of the Portfolio Committee (GF/B18/5). The QA Policy shall come into effect on 1 July 2009 and shall replace the Global Fund's previous policy for the quality assurance of pharmaceutical products (as approved at the Third Board meeting and amended at subsequent Board meetings).
The Board authorizes the Secretariat to request the World Health Organization (WHO) to host the Expert Review Panel described in the QA Policy, and to conclude the necessary arrangements with the WHO.
The Board delegates to the Portfolio Committee the responsibility for overseeing the implementation of the QA Policy, including the establishment of the Expert Review Panel. The Board requests the Secretariat to provide the Portfolio Committee with an update to review the implementation of the QA Policy at the Portfolio Committee's final meeting in 2009, and thereafter, as requested by the Portfolio Committee.
The Board also requests the Secretariat, under the oversight of the Portfolio Committee, to review the current status of quality assurance for diagnostic products and make recommendations. The Board requests the Portfolio Committee to report the findings of this review at the Board's final meeting in 2009.
The budgetary implications of this decision point in 2009 amount to US$ 1,245,000 which includes an allocation for 2 staff positions. (The cost will be covered by the budget contingency.)